1. 1232PModel-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types. (23rd October 2018) Authors: Zhao, X; Shen, J; Gopalakrishnan, M; Feng, Y; Schmidt, B J; Statkevich, P; Kelleher, T; Rashford, M; Ivaturi, V; Gobburu, J V S; Agrawal, S; Bello, A; Roy, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Should Pharmacometrics Be Training the Next R&D President?. Issue 6 (12th March 2014) Authors: Gobburu, J V S Journal: Clinical pharmacology & therapeutics Issue: Volume 95:Issue 6(2014) Page Start: 579 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗